21:43 , Jul 12, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: June 2018

New Therapeutic Targets and Biomarkers: June 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2018. Therapeutic targets are defined as any protein, gene or other...
16:49 , Jun 21, 2018 |  BC Innovations  |  Translation in Brief

PHIP the script

Cancers lacking key molecular signatures targeted by precision therapies are among the most challenging to treat, but a new study has identified a target, PHIP, for three of those difficult tumor types. A group led...
19:06 , Jun 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer; non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest inhibiting PHIP could help treat triple-negative breast cancer (TNBC) and NSCLC. In two human TNBC cell lines, shRNA targeting PHIP decreased...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

California Pacific Medical Center Research Institute, Insys deal

The institute granted Insys an exclusive license to the institute's patent rights covering the use of the biotech's cannabidiol (CBD) to treat glioblastoma multiforme (GBM). The small molecule synthetic cannabidiol has Orphan Drug designation in...
07:00 , Oct 13, 2011 |  BC Innovations  |  Cover Story

Going antiviral in brain cancer

A Karolinska Institute -led team has shown that targeting cytomegalovirus and/or inhibiting COX-2 could help treat medulloblastoma, the most common type of pediatric brain tumor. 1 The research presents a repurposing opportunity for companies with...
08:00 , Oct 31, 1994 |  BC Week In Review  |  Company News

Oncor, OncorMed deal

The BRUSH1 gene, discovered at the California Pacific Medical Center Research Institute (CPMC) in San Francisco, codes for a putative tumor suppressor gene expressed by breast epithelial cells that appears to be present in 30-50...